Status:
COMPLETED
Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
Lead Sponsor:
S. Andrea Hospital
Conditions:
Hereditary Ataxia
Multiple Sclerosis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Cerebellar disorders are often disabling and symptomatic therapies are limited to few options that are partially effective. It seems therefore appropriate to search for additional approaches. Purkinj...
Detailed Description
Forty patients with chronic cerebellar ataxia will be enrolled in a double-bind, randomized, placebo-controlled trial. By central randomisation, patients will take 50 mg of riluzole or placebo twice ...
Eligibility Criteria
Inclusion
- Patients with cerebellar degeneration (heredoataxias, sporadic idiopathic ataxia, multiple system atrophy type C)
- Patients who meet McDonald criteria for probable or definite multiple sclerosis (MS) with chronic cerebellar ataxia (not acute cerebellar ataxia due to relapse)
- Age between 18 and 80 years
Exclusion
- Ataxia due to other diseases
- Acute cerebellar ataxia
- Use of other drugs for chronic ataxia
- Serious concomitant illnesses (cardiac arrhythmias, haematological and hepatic diseases)
- Pregnancy or breast feeding
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00202397
Start Date
June 1 2005
End Date
August 1 2008
Last Update
December 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
S.Andrea Hospital - University of Rome "La Sapienza"
Rome, Italy, 00100